ZD6474(Vandetanib) + Alimta Combo Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

NCT00390000

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00071136

Lung Neoplasms

COMPLETED PHASE1/PHASE2

Comparing 3 Schedules of Alimta Plus Gemzar

NCT00034606

Carcinoma, Non-Small-Cell Lung Lung Neoplasms Neoplasms

COMPLETED PHASE2

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial

NCT00061451

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE2

Alimta and Gemcitabine in Non-Small Cell Lung Cancer

NCT00434135

Non-Small Cell Lung Cancer Stage IIIB or IV

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma Non-Small Cell Lung Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZD6474 (vandetanib) 100mg

Group Type EXPERIMENTAL

ZD6474 (vandetanib) 100mg

Intervention Type DRUG

once daily oral tablet

pemetrexed

Intervention Type DRUG

intravenous infusion

ZD6474 (vandetanib) 300mg

Group Type EXPERIMENTAL

pemetrexed

Intervention Type DRUG

intravenous infusion

ZD6474 (vandetanib) 300mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZD6474 (vandetanib) 100mg

once daily oral tablet

Intervention Type DRUG

pemetrexed

intravenous infusion

Intervention Type DRUG

ZD6474 (vandetanib) 300mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ZACTIMA™ Alimta® ZACTIMA™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed advanced or metastatic non-small cell lung cancer
* Failure of first-line chemotherapy
* 1 or more measurable lesion by RECIST

Exclusion Criteria

* Previous chemotherapy or radiotherapy within 4 weeks
* Significant cardiac events, arrythmias or other cardiac conditions
* Unacceptable laboratory measurements

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No